Gastrointestinal stromal tumour of the pharynx

This documents the case of a 55-year-old female presenting with a solitary polypoidal tumour of the pharynx. Histological examination revealed features consistent with a gastrointestinal stromal tumour. Although well described elsewhere in the gastrointestinal tract, from our literature search, this is the first reported case of such a tumour occurring in the pharynx

Download Full-text

Gastric IgG4-Related Autoimmune Fibrosclerosing Pseudotumour: A Novel Location

ISRN Gastroenterology ◽

10.5402/2011/873087 ◽

2011 ◽

Vol 2011 ◽

pp. 1-3 ◽

Cited By ~ 24

Author(s):

Katie E. Rollins ◽

Samir P. Mehta ◽

Maria O'Donovan ◽

Peter M. Safranek

Keyword(s):

Weight Loss ◽

Histological Examination ◽

Laparoscopic Resection ◽

Gastrointestinal Stromal Tumour ◽

Stromal Tumour ◽

Gastric Body ◽

Resected Specimen

We describe the first reported case of an IgG4-related autoimmune fibrosclerosing pseudotumour located in the stomach of a 75-year old woman presenting with weight loss and vomiting. A lesion was detected in the gastric body at endoscopy. Subsequent characterisation by CT was suggestive of a gastrointestinal stromal tumour. Following laparoscopic resection, the patient recovered uneventfully. Histological examination of the resected specimen revealed an IgG4-related fibrosclerosing pseudotumour, a novel location for this histopathological entity.

Download Full-text

Gastrointestinal stromal tumour and other mesenchymal tumours of the gastrointestinal tract: the role of immunohistochemistry in an evolving era of molecular diagnostics

Diagnostic Histopathology ◽

10.1016/j.mpdhp.2015.03.001 ◽

2015 ◽

Vol 21 (3) ◽

pp. 99-107

Author(s):

Leona A. Doyle

Keyword(s):

Gastrointestinal Tract ◽

Molecular Diagnostics ◽

Gastrointestinal Stromal Tumour ◽

Stromal Tumour ◽

Mesenchymal Tumours

Download Full-text

A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST)

Sarcoma ◽

10.1080/1357714021000045217 ◽

2002 ◽

Vol 6 (3) ◽

pp. 83-87 ◽

Cited By ~ 3

Author(s):

Ian Judson ◽

Michael Leahy ◽

Jeremy Whelan ◽

Paul Lorigan ◽

Mark Verrill ◽

...

Keyword(s):

Gastrointestinal Tract ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Multidisciplinary Team ◽

Kinase Inhibitor ◽

Gastrointestinal Stromal Tumour ◽

Accurate Diagnosis ◽

Stromal Tumour ◽

Mesenchymal Tumour ◽

Experienced Personnel

Gastrointestinal stromal tumour (GIST) is the commonest mesenchymal tumour to affect the gastrointestinal tract. Appropriate management requires accurate diagnosis and the skills of a multidisciplinary team. Surgery is the only curative treatment option and should be performed whenever feasible, by experienced personnel. For patients with advanced unresectable or metastatic disease, the receptor tyrosine kinase inhibitor imatinib offers effective therapy and can provide effective palliation for the majority of patients with this disease. The background to this recent development and a guideline for the management of GIST is proposed.

Download Full-text

Extragastrointestinal stromal tumour (EGIST) presented as a mesenteric and retroperitoneal mass

BMJ Case Reports ◽

10.1136/bcr-2019-232481 ◽

2019 ◽

Vol 12 (12) ◽

pp. e232481 ◽

Cited By ~ 1

Author(s):

Carlos Costa Almeida ◽

Teresa Vieira Caroço ◽

Miguel Albano ◽

Luís Carvalho

Keyword(s):

Gastrointestinal Tract ◽

Pluripotent Stem Cells ◽

Gastrointestinal Stromal Tumour ◽

Stromal Tumour ◽

Molecular Characteristics ◽

Tumour Mass ◽

Retroperitoneal Mass ◽

Low Threshold ◽

Worse Prognosis

Extragastrointestinal stromal tumour (EGIST) occurs outside the gastrointestinal tract and has histopathological and molecular characteristics similar to gastrointestinal stromal tumour (GIST). This tumour is rare and aggressive. A male patient was admitted with anaemia and lower limb oedema. CT scan showed a tumour in the mesentery and retroperitoneum, suspected to be a small bowel GIST. During laparotomy an unresectable mass was found compressing the retroperitoneal structures. Pathology and immunohistochemistry (CD117) confirmed an EGIST. EGIST arises from Cajal-like cells or from pluripotent stem cells outside the gastrointestinal tract. It is aggressive and has a worse prognosis than GIST. Immunohistochemistry is crucial for diagnosis. Surgery aimed at debulking as much of a tumour mass as possible is the cornerstone of treatment. The role of imatinib is not clear. EGIST is rare and has a bad prognosis, and there is no consensus on grading and management. A low threshold of suspicion is crucial for early diagnosis.

Download Full-text